New Therapies for Relapsed Myeloma

More Information

What kind of information would you like to request?     More Information       Make a Referral

Leave this field empty

Dan Vogl, MD, MSCE, examines new therapies for relapsed myeloma by reviewing recent efficacy, safety and outcomes clinical trials. Agents reviewed include the proteasome inhibitors, the histone deacetylase inhibitors, the monoclonal antibodies and and ibrutinib, vemurafinib and other agents now entering the field.

Comments